United Therapeutics Shares Key Insights at PVRI Annual Congress 2025

United Therapeutics Showcases Clinical Insights at PVRI Congress

United Therapeutics Corporation (Nasdaq: UTHR), a renowned public benefit corporation, has exciting news as they prepare to present at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress. The event will highlight the latest clinical data across their commercial and development portfolio focusing on pulmonary hypertension (PH). Scheduled from January 29 to February 1, 2025, in Rio de Janeiro, this congress promises to be a significant opportunity for knowledge-sharing and collaboration.

Presentations and Speaking Engagements

This year, United Therapeutics will showcase five informative posters that summarize their extensive research in pulmonary hypertension. Additionally, key professionals from the company will actively participate in vital discussions at two speaking events. With a commitment to advancing understanding in this critical field, United Therapeutics is poised to make a lasting impression at the congress.

Highlighted Research Posters

The posters that will be on display include notable topics such as:

• Real-World Dosing of Tyvaso DPI: A detailed study by Burger et al., focusing on the medication's real-world application in different forms of pulmonary hypertension.
• BREEZE Optional Extension Phase: Insights into long-term outcomes with Tyvaso DPI by Spikes et al., showcasing its effectiveness in managing pulmonary arterial hypertension.
• Interim Results from PHINDER: Research by Beck et al. exploring screening methods for pulmonary hypertension in patients with interstitial lung disease.
• Inhaled Treprostinil Analysis: Conducted by Argula et al., examining the effects of inhaled treprostinil in intermediate-high risk patients.
• Participant Experiences from ARTISAN: An investigation into patient-reported experiences in the ARTISAN study led by Tomson et al.

Engaging the Community

United Therapeutics is honored to sponsor events aimed at empowering women in the pulmonary hypertension community, such as the Women in PH Luncheon. This initiative aims to support educational opportunities and enhance professional networks.

Sessions to Look Forward To

Key sessions on January 29 include:

Real World Evidence Overview

This session, chaired by Kellie Morland, PharmD, will delve into real-world data from 10:40 AM to 11:15 AM, emphasizing its importance in clinical decision-making.

Clinical Trial Insights

Another highlight is the session titled "Challenges of Clinical Trial Design, Conduct & Endpoints," presented by C.Q. Deng, M.D., Ph.D., which promises insights pertinent to modern clinical trial frameworks.

About Tyvaso and Its Indications

Tyvaso (treprostinil) is a crucial therapy for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). These conditions significantly impact patients' quality of life, making effective treatment options critical.

Tyvaso and Tyvaso DPI are proven to improve exercise ability in PAH patients, particularly those classified as NYHA Functional Class III. The flexibility in dosing allows treatment adjustments tailored to patients' daily activities.

Safety Considerations

Both products are systemic and pulmonary vasodilators, and while beneficial, they require careful monitoring to prevent complications such as hypotension or bleeding. It is essential for healthcare providers to ensure optimal treatment protocols to maximize patient safety and therapeutic effectiveness.

United Therapeutics: A Commitment to Innovation

United Therapeutics stands at the forefront of medical innovation, driven by a mission to meet the unmet needs of patients. As the first publicly-traded biotech company structured as a public benefit corporation, they focus on expanding the availability of transplantable organs and developing new therapies.

The company emphasizes the need for fostering an inclusive community and remains dedicated to providing resources and support to healthcare professionals and patients alike.

Frequently Asked Questions

What is the significance of the PVRI 2025 Annual Congress for United Therapeutics?

This congress serves as a platform for United Therapeutics to present important clinical findings and engage with the medical community on advancements in treating pulmonary hypertension.

What research will United Therapeutics present?

They will present five posters highlighting real-world data, long-term outcomes, interim results from studies, and patient experiences related to Tyvaso and pulmonary hypertension.

Who are the key speakers from United Therapeutics at the congress?

Notable speakers include Kellie Morland, PharmD, and C.Q. Deng, M.D., Ph.D., who will discuss real-world evidence and clinical trial designs.

What are Tyvaso and Tyvaso DPI used for?

Both medications are indicated for treating pulmonary arterial hypertension and improving exercise ability in affected patients.

How does United Therapeutics support women in pulmonary hypertension?

They sponsor events aimed at empowering women professionals in the field and promote educational opportunities to strengthen networks within the community.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.